Novartis Gets CDSCO Panel Nod to study Remibrutinib to treat chronic spontaneous urticaria Dr. Divya Colin8 Dec 2023 6:00 PM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Acupuncture may Improve Outcomes of Chronic Urticaria Jacinthlyn Sylvia27 Nov 2023 10:00 AM ISTIn a recent randomized multicenter trial published in the Annals of Internal Medicine found the effectiveness of acupuncture for patients grappling...
Remibrutinib new option beyond antihistamines for managing chronic spontaneous urticaria Aditi23 Nov 2023 2:30 PM ISTRemibrutinib (LOU064) is a highly selective Bruton's tyrosine kinase inhibitor (BTKi). It has demonstrated the ability to effectively manage symptoms...
Acupuncture may offer limited relief to patients with chronic spontaneous urticaria Dr. Kamal Kant Kohli14 Nov 2023 9:15 PM ISTA randomized controlled trial that included more than 300 people diagnosed with chronic spontaneous urticaria (CSU), or hives, found that acupuncture...
Remibrutinib improves outcomes in Chronic Spontaneous Urticaria Patients Jacinthlyn Sylvia31 Oct 2023 2:30 AM ISTPatients with chronic spontaneous urticaria (CSU) who have found little relief with existing treatments, a novel drug called Remibrutinib (LOU064) has...
Require additional efficacy data for Dupixent approval for chronic spontaneous urticaria: USFDA to Sanofi Ruchika Sharma23 Oct 2023 4:44 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Elevated marker of IgE-mediated mast cell activation predicts omalizumab response in chronic spontaneous urticaria Medha Baranwal19 Sept 2023 10:15 AM ISTOmalizumab is an anti-IgE monoclonal antibody that is suggested to be an effective treatment in chronic spontaneous urticaria.
Remibrutinib could be new effective and fast-acting oral treatment option for chronic spontaneous urticaria: Phase 3 trials Dr. Kamal Kant Kohli12 Aug 2023 11:15 AM ISTSwitzerland: The phase 3 trials REMIX-1 and REMIX-2 have yielded positive top-line results, as announced by Novartis. Trials assessed remibrutinib 25...
Dupilumab improves urticaria activity and QoL in patients with chronic spontaneous urticaria Medha Baranwal13 March 2023 8:00 PM ISTUSA: A recent study has found that patients with chronic spontaneous urticaria treated with dupilumab experienced a significant improvement in quality...
Sanofi Dupixent application for treatment of chronic spontaneous urticaria in adults, adolescents accepted for USFDA review Ruchika Sharma7 March 2023 3:30 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Sanofi, Regeneron Pharma announce positive Phase 3 data for Dupixent in adults with uncontrolled prurigo nodularis Ruchika Sharma10 Sept 2022 12:56 PM ISTPeople with prurigo nodularis experience intense, persistent itch, with thick skin lesions (called nodules) that can cover most of the body.
Dupilumab notably reduces hives and hitch in patients with chronic spontaneous urticaria: Study Medha Baranwal5 May 2022 10:15 AM ISTUSA: Results from a phase 3 trial revealed that dupilumab is well-tolerated and causes significant improvement in patients with H1...
